Skip to main
VCEL
VCEL logo

Vericel (VCEL) Stock Forecast & Price Target

Vericel (VCEL) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vericel Corp's recent performance highlights a robust growth trajectory, with NexoBrid hospital orders surging 40% quarter-over-quarter and an annual increase in the burn care franchise of 22% year-over-year, reaching $39.9 million for FY2024. Management's commitment to expand the burn care salesforce is anticipated to further enhance growth, projecting an 8.3% increase for 2025, while MACI also demonstrated strong momentum, achieving $68.3 million in 4Q24, a 21% increase from the previous year. With significant upcoming product launches and a positive trend in MACI implant metrics, Vericel is positioned for accelerated revenue growth and an expected profit inflection, indicative of its potential for sustained market performance.

Bears say

Vericel Corporation reported preliminary revenue results that fell short of expectations, notably with lower contributions from its products, specifically Epicel and NexoBrid, indicating potential weakened demand. The company's fourth-quarter results showed a top-line miss, coming in at $75.4 million, which was below earlier forecasts and raises concerns about growth prospects amid potential end-market weaknesses and competitive dynamics. Key risks identified include recession impacts, operational disruptions, and underperformance in patient treatment conversions, all contributing to a cautious outlook on the company's short-term financial performance.

Vericel (VCEL) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vericel (VCEL) Forecast

Analysts have given Vericel (VCEL) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Vericel (VCEL) has a Strong Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vericel (VCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.